Isolation and characterization of human antioxidized LDL autoantibodies

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 16, Issue 2, 1996, Pages 222-229

  Mironova, Marina ^a   Virella, G ^a   Lopes Virella, Maria F ^b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b RALPH H JOHNSON VA MEDICAL CENTER   (United States)

Author keywords

affinity constants; antioxidized LDL autoantibody isolation; arteriosclerosis; autoimmunity; isotypes

Indexed keywords

AUTOANTIBODY; CARDIOLIPIN; FC RECEPTOR; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G3; MALONALDEHYDE; OXIDIZED LOW DENSITY LIPOPROTEIN;

ADULT; AFFINITY CHROMATOGRAPHY; AGED; ARTERIOSCLEROSIS; ARTICLE; AUTOIMMUNITY; BINDING AFFINITY; CLINICAL ARTICLE; COMPLEMENT ACTIVATION; CONTROLLED STUDY; DISSOCIATION CONSTANT; ETIOLOGY; FEMALE; HUMAN; HUMAN CELL; LIPID OXIDATION; MALE; PHAGOCYTE; PRIORITY JOURNAL;

EID: 0030044225     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.16.2.222     Document Type: Article

References (52)

1. Steinbrecher UP, Parthasarathy S, Leake DS, Witztum JL, Steinberg D. Modification of low density lipoprotein by endothelial cells involves lipid peroxidation and degradation of low density lipoprotein phospholipids. Proc Natl Acad Sci U S A. 1984;81: 3883-3887.
2. Morel DW, DiCorleto PE, Chisolm GM. Endothelial and smooth muscle cells alter low-density lipoprotein in vitro by free radical oxidation. Arteriosclerosis. 1984;4:357-364.
3. Cathcart MK, Morel DW, Chisolm GM. Monocyte and neutrophils oxidize low density lipoprotein making it cytotoxic. J Leukoc Biol. 1985;38:341-350.
4. Parthasarathy S, Printz DJ, Boyd D, Joy L, Steinberg D. Macrophage oxidation of low-density lipoprotein generates a modified form recognized by the scavenger receptor. Arteriosclerosis. 1986;6: 505-510.
5. Palinski W, Rosenfeld ME, Ylä-Herttuala S, Gurtner GC, Socher SS, Butler SW, Parthasarathy S, Carew TE, Steinberg D, Witztum JL. Low density lipoprotein undergoes oxidative modification in vivo. Proc Natl Acad Sci U S A. 1989;86:1372-1376.
6. Haberland ME, Fong D, Cheng L. Malonyldialdehyde-altered protein occurs in atheroma of Watanabe heritable hyperlipidemic rabbits. Science. 1988;241:215-218.
7. Yla-Herttuala S, Palinski W, Rosenfeld ME, Steinberg D, Witztum JL. Lipoproteins in normal and atherosclerotic aorta. Eur Heart J. 1990;11(suppl E):88-99.
8. Yla-Herttuala S, Palinski W, Rosenfeld ME, Parthasarathy S, Carew TE, Butler S, Witztum JL, Steinberg D. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J Clin Invest. 1989;84:1086-1095.
9. Carew TE, Schwenke DC, Steinberg D. Antiatherogenic effect of probucol unrelated to its hypocholesterolemic effect: evidence that antioxidants in vivo can selectively inhibit LDL degradation in macrophage-rich fatty streaks and slow the progression of atherosclerosis in the Watanabe heritable hyperlipidemic rabbit. Proc Natl Acad Sci U S A. 1987;84:7725-7729.
10. Kita T, Nagano Y, Yokode ML, Ishii K, Kume N, Ooshima A, Yoshida H, Kawai C. Probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbit, an animal model for familial hypercholesterolemia. Proc Natl Acad Sci U S A. 1987;84:5928-5931.
11. Regnstrom J, Nilsson J, Tornvall P, Landou C, Hamsten A. Susceptibility to LDL oxidation and coronary atherosclerosis in man. Lancet. 1991;339:1183-1186.
12. Chiu H-C, Jeng J-R, Shieh S-ML. Increased oxidizability of plasma LDL from patients with coronary heart disease. Biochim Biophys Acta. 1994;225:200-208.
13. Cominacini L, Garbi U, Pastorino AM, Davoli A, Campagnola ML, De Santis A, Pasini C, Faccini GB, Trevisan MT, Bertozzo L, Pasini F, Lo Cascio V. Predisposition to LDL oxidation in patients with and without angiographically established coronary artery disease. Atherosclerosis. 1993;99:63-70.
14. Andrews B, Burnand K, Paganga G, Browse N, Rice-Evans C, Sommerville K, Leake D, Taub N. Oxidizability of LDL in patients with carotid or femoral artery atherosclerosis. Atherosclerosis. 1995; 112:77-84.
15. Steinberg D, Witztum JL. Lipoproteins and atherogenesis. JAMA. 1990;264:3047-3052.
16. Berliner JA, Territo MC, Sevanian A, Ramin S, Kim JA. Bamshad B, Esterson ML, Fogelman A. Minimally modified low density lipoprotein stimulates monocyte-endothelial interactions. J Clin Invest. 1990;85:1260-1266.
17. Jeng JR, Chang CH, Shieh SM, Chiu HC. Oxidized low-density lipoprotein enchances monocyte-endothelial cell binding against shear stress-induced detachment. Biochim Biophys Acta. 1993;1178: 221-227.
18. Morel DW, Hessler JR, Chisolm GM. Low density lipoprotein cytotoxicity induced by free-radical peroxidation of lipid. J Lipid Res. 1983;24:1070-1076.
19. Orekhov AN, Tertov VV, Kabakov AE, Adamova TY, Pokrovsky SN, Smirnov VN. Autoantibodies against modified low density lipoprotein: nonlipid factor of blood plasma that stimulates foam cell formation. Arterioscler Thromb. 1991;11:316-326.
20. Virella G, Virella I, Leman RB, Pryor MB, Lopes-Virella MF. Anti-oxidized low-density lipoprotein antibodies in patients with coronary heart disease and normal healthy volunteers, Int J Clin Lab Res. 1993;23:95-101.
21. Salonen JT, Ylä-Herttuala S, Yamamoto R, Butler S, Korpela H, Salonen R, Nyyssönen K, Palinski W, Witztum JL. Autoantibody against oxidized LDL and progression of carotid atherosclerosis. Lancet. 1992;339:883-887.
22. Klimov AN, Denisenko AD, Vinogradov AG, Nagornev VA, Pivovarova YI, Sitnikova OD, Pleskov AG. Accumulation of cholesteryl esters in macrophages incubated with human lipoprotein-antibody autoimmune complex. Atherosclerosis. 1988;74:41-46.
23. Tertov VV, Orekhov AN. Kacharava AG, Sobenin IA, Perova NV, Smirnov VN. Low density lipoprotein-containing circulating immune complexes and coronary atherosclerosis. Exp Mol Pathol. 1990;52:300-308.
24. Lopes-Virella MF, Griffith RL, Shunk KA, Virella G. Enhanced uptake and impaired intracellular metabolism of low density lipoprotein complexed with anti-low density lipoprotein antibodies. Arterioscler Thromb. 1991;11:1356-1367.
25. Klimov AN, Denisenko AD, Popov AV, Nagornev VA, Pleskov VM, Vinogradov AG, Denisenko TV, Magracheva EY, Kheifes GM, Kuznetzov AS. Lipoprotein-antibody immune complexes: their catabolism and role in foam cell formation. Atherosclerosis. 1985;58:1-15.
26. Gissinger C, Virella GT, Lopes-Virella MF. Erythrocyte-bound low density lipoprotein (LDL) immune complexes lead to cholesteryl ester accumulation in human monocyte derived macrophages. Clin Immunol Immunopathol. 1991;59:37-51.
27. Gisinger C, Lopes-Virella MF. Lipoprotein-immune complexes and diabetic vascular complications. Diabetes. 1992;41:92-96.
28. Griffith RL, Virella GT, Stevenson HC, Lopes-Virella MF. Low density lipoprotein metabolism by human macrophages activated with low density lipoprotein immune complexes. J Exp Med. 1988; 168:1041-1059.
29. Virella G, Muñoz JF, Galbraith GMP, Gissinger C, Chassereau C, Lopes-Virella MF. Activation of human monocyte-derived macrophages by immune complexes containing low density lipoprotein. Clin Immunol Immunopathol. 1995;75:179-189.
30. Maggi E, Chiesa R, Melissano G, Castellano R, Astore D, Grossi A, Finardi G, Bellomo G. LDL oxidation in patients with severe carotid atherosclerosis: a study of in vitro and in vivo oxidation markers. Arterioscler Thromb. 1994;14:1892-1899.
31. Bergmark C, Wu R, De Faire U, Lefvert AK, Swedenborg J. Patients with early-onset peripheral vascular disease have increased level of autoantibodies against oxidized LDL. Arterioscler Thromb Vasc Biol. 1995;15:441-445.
32. Schumacher ML, Eber B, Tatzber F, Kaufmann P, Esterbauer H, Klein W. LDL oxidation and coronary atherosclerosis. Lancet. 1992;340:123. Letter.
33. Salmon S, Maziere C, Theron L, Beucler I, Ayrault-Jarrier ML, Goldsten S, Polonovski J. Immunological detection of low-density lipoproteins modified by malondialdehyde in vitro or in vivo. Biochim Biophys Acta. 1987;920:215-220.
34. Virella G, Mironova M, Lopes-Virella MF. Comparing assays of antibodies to modified low-density lipoproteins. Clin Chem. 1995; 41:324-325.
35. Lopes-Virella MF, Sherer GK, Lees AM, Wohltmann H, Mayfield R, Sagel J, LeRoy EC. Surface binding, internalization, and degradation by cultured human fibroblasts of LDL isolated from type 1 (insulin-dependent) diabetic patients: changes with metabolic control. Diabetologia. 1982;22:430-436.
36. Steinbrecher UP. Oxidation of human low density lipoprotein results in derivatization of lysine residues of apolipoprotein B by lipid peroxide decomposition products. J Biol Chem. 1987;262: 3603-3608.
37. Haberland ME, Fogelman AM, Edwards PA. Specificity of receptor-mediated recognition of malondialdehyde-modified low density lipoproteins. Proc Nat Acad Sci U S A. 1982;79:1712-1716.
38. Kim RS, LaBella FS. Comparison of analytical methods for monitoring auto-oxidation profiles of authentic lipids. J Lipid Res. 1987; 28:1110-1117.
39. Cominacini L, Garbin U, Davoli A, Micciolo R, Bosello O, Gaviraghi G, Scuro LA, Pastorino AM. A simple test for predisposition to LDL oxidation based on the fluorescence development during copper-catalyzed oxidative modification. J Lipid Res. 1991; 32:349-358.
40. Virella G. Antigen-antibody reactions. In: Virella G, ed. Introduction to Medical Immunology. 3rd ed. New York, NY: Marcel Dekker; 1993:126-127.
41. Friguet B, Chaffotte AF, Djavadi-Ochaniace L, Goldberg ME. Measurements of the true affinity constant in solution of antigen- antibody complexes by enzyme-immunosorbent assay. J Immunol Methods. 1985;77:305-319.
42. Libby P, Hansson GK. Involvement of the immune system in human atherogenesis: current knowledge and unanswered questions. Lab Invest. 1991;64:5-15.
43. Lopes-Virella MF, Virella G. Short analytical review: atherosclerosis and autoimmunity. Clin Immunol Immunopathol. 1994;73: 155-167.
44. Wick G, Schett G, Amberger A, Kleindienst R, Xu Q. Is atherosclerosis an immunologically mediated disease? Immunology Today. 1995;16:27-33.
45. Avogaro P, Bittolo Bon G, Cazzolato G. Presence of a modified low density lipoprotein in humans. Arteriosclerosis. 1988;8:79-87.
46. Hoff FH, Gaubatz JW. Isolation, purification, and characterization of a lipoprotein containing apo B from the human aorta. Atherosclerosis. 1982;42:273-297.
47. Hoff H. O'Neil J. Lesion-derived low density lipoprotein and oxidized low density lipoprotein share a lability for aggregation, leading to enchanced macrophage degradation. Arterioscler Thromb. 1991;11:1209-1222.
48. Beaumont JL, Beaumont V. Immunological aspects of atherosclerosis. Atherosclerosis Rev. 1978;3:133-146.
49. Virella G, Wang AC. Biosynthesis, metabolism and biological properties of immunoglobulins. In: Virelia G, ed. Introduction to Medical Immunology. 3rd ed. New York, NY: Marcel Dekker; 1993:91-102.
50. Virella G. Immune complex diseases. In: Virella G, ed. Introduction to Medical Immunology. 3rd ed. New York, NY: Marcel Dekker; 1993:379-396.
51. Palinski W, Yla-Herttuala S, Rosenfeld ME, Butler SW, Socher SA, Parthasarathy S, Curtiss LK, Witztum JL. Antisera and monoclonal antibodies specific for epitopes generated during oxidative modification of low density lipoprotein. Arteriosclerosis. 1990;10: 325-335.
52. Vaarala O, Alfthan G, Jauhiainen ML, Leirisalo-Repo ML, Aho K, Palosuo T. Crossreaction between antibodies to oxidized low- density lipoprotein and to cardiolipin in systemic lupus crythematosus. Lancet. 1993;341:923-925.